225 232
226 233
227 234
228 235
229 236
230 237
231 238
232 239
233 240
234 241
235 242
236 243
237 244
238 245
239 246
240 247
241 248
242 249
243 250
244 251
245 252
246 253
247 254
248 255
249 256
250 257
251 258
252 259
253 261
254 262
255 263
256 264
257 265
258 266
259 267
260 268
261 269
262 270
263 271
264 272
265 273
266 274
267 275
268 276
269 277
270 278
271 279
272 281
273 282
274 283
275 284
276 285
277 286
278 287
279 289
280 290
281 291
282 292
283 293
284 294
285 295
286 296
287 297
288 298
289 299
290 300
291 301
292 302
293 303
294 304
295 305
296 306
297 307
298 308
299 309
300 310
301 311
302 312
303 313
304 315
305 316
306 317
307 318
308 319
309 320
310 321
311 322
312 323
313 324
314 325
315 326
316 327
317 329
318 330
319 331
320 332
321 333
322 334
323 335
324 337
325 338
326 339
327 340
328 341
329 342
330 343
Genome Editing in Drug Discovery
Edited by
Marcello Maresca
AstraZeneca, BioPharmaceuticals R&D
Mölndal, Sweden
Sumit Deswal
AstraZeneca, BioPharmaceuticals R&D
Mölndal, Sweden
This edition first published 2022. © 2022 John Wiley & Sons, Inc.
All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by law. Advice on how to obtain permission to reuse material from this title is available at http://www.wiley.com/go/permissions.
The right of Marcello Maresca and Sumit Deswal to be identified